Effects of valsartan and nebivolol on blood pressure, QT dispersion and left ventricular hypertrophy in hypertensive patients Hipertansif hastalarda valsartan ve nebivololun, kan basinci, QT dağilimi ve sol ventrikül hipertrofisi üzerine etkileri

作者: L. Negrea , Sorana D. Bolboacă

DOI:

关键词:

摘要: Objectives: The aim of this study was to analyze the antihypertensive effect Valsartan and Nebivolol their effects on QT dispersion left ventricular hypertrophy (LVH) in treatment naive hypertensive patients. Methods: A prospective with a six-month follow-up conducted patients LVH mild/ moderate essential hypertension. were randomly assigned (80 160 mg/day) or (5 10 groups. group consisted 108 patients, 55 53 group. Results: range mean systolic blood pressure (SBP) varied from 152±17 (baseline) 132±17 mmHg (follow-up) (p<0.001); 146±13 125±14 (p<0.001). decrease diastolic (DBP) 9.5±2.5 12.3±5.0 significant reduction corrected (Bazett’s formula) observed both groups, slightly higher Echocardiography showed ventricle mass (LVM) indices (p<0.05) groups greater Conclusion: as effective reducing 24 hour- SBP after 6 month treatment. proved be superior DBP. Both therapies LVH; interval indexes relation LVM reduction.

参考文章(36)
W. P. Castelli, D. Levy, J. Stokes, M. Feinleib, S. J. Anderson, R. J. Garrison, W. B. Kannel, D. D. Savage, The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation. ,vol. 75, ,(1987)
André Regazzi Gerk, Elias Pimentel Gouvea, Emerson C. Perin, Valéria Martins Soares Santos, Denilson Campos de Albuquerque, Francisco Manes Albanesi Filho, Ricardo Mourilhe Rocha, Guilherme Vianna Silva, Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure is there a difference in the elderly? Texas Heart Institute Journal. ,vol. 30, pp. 176- 179 ,(2003)
S Balanescu, M Galinier, J Fourcade, M Dorobantu, JP Albenque, P Massabuau, JM Fauvel, JP Bounhoure, None, Correlation between QT interval dispersion and ventricular arrhythmia in hypertension Archives Des Maladies Du Coeur Et Des Vaisseaux. ,vol. 89, pp. 987- 990 ,(1996)
Noboru Toda, Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics Pharmacology & Therapeutics. ,vol. 100, pp. 215- 234 ,(2003) , 10.1016/J.PHARMTHERA.2003.09.001
Pitt O. Lim, Marleen Nys, Abdul A. O. Naas, Allan D. Struthers, Mary Osbakken, Thomas M. MacDonald, Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension. ,vol. 33, pp. 713- 718 ,(1999) , 10.1161/01.HYP.33.2.713
Diego F Dávila, Jose H Donis, Rodolfo Odreman, Maite Gonzalez, Agustin Landaeta, None, Patterns of left ventricular hypertrophy in essential hypertension: Should echocardiography guide the pharmacological treatment? International Journal of Cardiology. ,vol. 124, pp. 134- 138 ,(2008) , 10.1016/J.IJCARD.2007.01.089
Achille C. Pessina, Metabolic effects and safety profile of nebivolol. Journal of Cardiovascular Pharmacology. ,vol. 38, ,(2001) , 10.1097/00005344-200112003-00006
Silvia G. Priori, Peter J. Schwartz, Carlo Napolitano, Raffaella Bloise, Elena Ronchetti, Massimiliano Grillo, Alessandro Vicentini, Carla Spazzolini, Janni Nastoli, Georgia Bottelli, Roberta Folli, Donata Cappelletti, Risk Stratification in the Long-QT Syndrome The New England Journal of Medicine. ,vol. 348, pp. 1866- 1874 ,(2003) , 10.1056/NEJMOA022147